TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21190037

Group type: EXPERIMENTAL
Intervention: 400(98%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 400(95%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 400(93%)
Number of subjects: 8
Study: 19533210

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17187274

Group type: EXPERIMENTAL
Intervention: A + HA group (arthroscopic knee joint lavage followed by 10 ml of 0.5% sodium hyaluronate)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group A (arthroscopic knee joint lavage without hyaluronic acid)
Number of subjects: 80
Study: 15006059

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP) plus sequential laparoscopic bladder diverticulectomy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Open bladder diverticulectomy and transvesical prostatectomy
Number of subjects: 25
Study: 11557928

Group type: EXPERIMENTAL
Intervention: Noncontact normothermic wound therapy (3 treatments daily, dressing warmed to 38 degrees C for 1 hour)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (moisture retentive dressings providing absorption as needed)
Number of subjects: 40
Study: 11398304

Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 50
Study: 8143475

Group type: EXPERIMENTAL
Intervention: Closed endotracheal suctioning
Number of subjects: 35

Group type: COMPARATOR
Intervention: Open endotracheal suctioning
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 35
Study: 2091073

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 111

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Combined treatment (Nitrendipine + Chlorthalidone)
Number of subjects: 111
Study: 792735

Group type: EXPERIMENTAL
Intervention: parsalmide
Number of subjects: 55

Group type: COMPARATOR
Intervention: phenylbutazone
Number of subjects: 55
Study: 31730174

Group type: EXPERIMENTAL
Intervention: Spironolactone-pioglitazone-metformin (SPIOMET) for 1 year
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) for 1 year
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy age- and BMI-matched girls (Control)
Number of subjects: 31
Study: 30938563

Group type: EXPERIMENTAL
Intervention: Consumer-decides (CD) approach to selecting hearing aids
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Audiology-based (AB) best practices trial
Number of subjects: 40

Group type: COMPARATOR
Intervention: CD-based placebo device
Number of subjects: 40
Study: 26976354

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 727

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 727
Study: 26333111

Group type: EXPERIMENTAL
Intervention: Handholding and spoken information (Experimental Group I)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Handholding only (Experimental Group II)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Experimental Groups (I and II)
Number of subjects: 94
Study: 24135894

Group type: EXPERIMENTAL
Intervention: 300 mg of avocado soybean unsaponifiables (ASU) for 3 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 14
Study: 21723697

Group type: EXPERIMENTAL
Intervention: RP-F
Number of subjects: 142

Group type: COMPARATOR
Intervention: RP
Number of subjects: 142
Study: 19261208

Group type: EXPERIMENTAL
Intervention: Parent-delivered compensatory education intervention over 12 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Parent-delivered compensatory education intervention
Number of subjects: 30
Study: 18181513

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 44
Study: 15013959

Group type: EXPERIMENTAL
Intervention: 60% oxygen
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 40% oxygen
Number of subjects: 204

Group type: COMPARATOR
Intervention: Air
Number of subjects: 204
Study: 10923219

Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.15 IU/kg body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Human insulin (0.15 IU/kg body weight)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 18

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insulin aspart and Human insulin
Number of subjects: 18
Study: 8834979

Group type: EXPERIMENTAL
Intervention: New regimen with a crisis programme including a milieu therapeutic setting
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38
Study: 1343612

Group type: EXPERIMENTAL
Intervention: Intravenous sedation with 30 mg of pentazocine and 5 mg of diazepam
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hematoma block with 20 cc of 1.5% Xylocaine
Number of subjects: 66
Study: 6364804

Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 75

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 75
Study: 30523161

Group type: EXPERIMENTAL
Intervention: Diaphragm pacing intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Routine respiratory measures (VC, maximal inspiratory pressure, SNIP, twitch transdiaphragmatic pressure)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inspiratory capacity (IC)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Supine fall in VC
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: IC, SNIP, and functional residual capacity
Number of subjects: 39
Study: 30055335

Group type: EXPERIMENTAL
Intervention: Intensive prolonged exposure therapy (exact details of dosage and duration not specified, but treatment is administered daily over a 3-week period)
Number of subjects: 0
Study: 27019339

Group type: EXPERIMENTAL
Intervention: Conventional CBT for primary disorder
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combined CBT for both disorders
Number of subjects: 86
Study: 23866103

Group type: EXPERIMENTAL
Intervention: Master Your Mood (MYM)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 244
Study: 22085869

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplementation
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Folic acid supplementation
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Iron-folic acid supplementation
Number of subjects: 1388
Study: 19452699

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Dapoxetine
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 4291
Study: 17531725

Group type: EXPERIMENTAL
Intervention: 0.7%-1.2% isoflurane
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: 3.5%-5.5% desflurane
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: 1.2%-1.9% sevoflurane
Number of subjects: 625
Study: 15090487

Group type: EXPERIMENTAL
Intervention: 60 degrees head-down tilt (HDT)
Number of subjects: 0
Study: 12079562

Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Recombinant human interleukin 2 (rhIL-2)
Number of subjects: 11
Study: 11013686

Group type: EXPERIMENTAL
Intervention: 50,000 IU urokinase instilled into the ventricles
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no urokinase)
Number of subjects: 21
Study: 7808223

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) mRNA levels in Alzheimer's disease patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poly (A)+ mRNA levels in Alzheimer's disease patients
Number of subjects: 0
Study: 2698946

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice a day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine AR (20 mg twice a day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (1 tablet twice a day)
Number of subjects: 11
Study: 1043

Group type: EXPERIMENTAL
Intervention: Bu 1014 (8‐chloro‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐1,5‐benzodiazepin‐2‐one)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31381231

Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subcutaneous Methotrexate (MTX)
Number of subjects: 28
Study: 28439994

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg once daily, adjustable to 100 or 25 mg as needed)
Number of subjects: 7834

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7834

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 7834
Study: 26028925

Group type: EXPERIMENTAL
Intervention: Acceptable sputum specimens for bacterial pneumonia
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sputum with ≥25 white blood cells/low-power field
Number of subjects: 77
Study: 23842572

Group type: EXPERIMENTAL
Intervention: Carpal tunnel release surgery
Number of subjects: 8
Study: 21946445

Group type: EXPERIMENTAL
Intervention: Colloidal silver and carbossimetyl beta glucan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 100
Study: 19775047

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway Supreme (LMAS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 70
Study: 17275886

Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 U, subcutaneous injections, once daily until ulcer healing or for a maximum of six months)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 15457352

Group type: EXPERIMENTAL
Intervention: Talc slurry (TS) 4 g
Number of subjects: 71

Group type: COMPARATOR
Intervention: Bleomycin (BL) 60 units
Number of subjects: 71
Study: 11037053

Group type: EXPERIMENTAL
Intervention: IL-2 presurgical immunotherapy (12 million IU/day for 3 days subcutaneously)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (without IL-2 presurgical immunotherapy)
Number of subjects: 14
Study: 9272407

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch renewed on a new skin location
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch renewed on the previous application site
Number of subjects: 20
Study: 8386652

Group type: EXPERIMENTAL
Intervention: Arm A: NCI regimen with vinblastine, etoposide, bleomycin and double dose cisplatin (PVeBV) 3 or 4 cycles Q3W
Number of subjects: 115

Group type: COMPARATOR
Intervention: Arm B: modified PVeBV protocol (bleomycin in continuous infusion) Q4W than a cycle of high-dose E + cyclophosphamide + P2 (PEC) and autologous bone marrow transplantation (ABMT)
Number of subjects: 115
Study: 3513504

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 28489694

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections
Number of subjects: 133

Group type: COMPARATOR
Intervention: Observation alone (control group)
Number of subjects: 133
Study: 26033153

Group type: EXPERIMENTAL
Intervention: MP‐MRI followed by 10‐ to 12‐core TRUS‐guided random biopsy and cognitive MRI/TRUS fusion targeted biopsy
Number of subjects: 130

Group type: COMPARATOR
Intervention: TRUS‐guided random biopsy alone
Number of subjects: 130
Study: 25700292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various interventions in clinical trials
Number of subjects: 0
Study: 23878212

Group type: EXPERIMENTAL
Intervention: Claritin advertisements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zyrtec advertisements
Number of subjects: 0
Study: 20850847

Group type: EXPERIMENTAL
Intervention: Low-dose insulin (100 pmol/L)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Medium-dose insulin (400 pmol/L)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (12 mmol/L)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide administration (to mimic sepsis)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Euglycemia (5 mmol/L)
Number of subjects: 24
Study: 18184849

Group type: EXPERIMENTAL
Intervention: Functional MR imaging (fMRI) with verb-generation, phonemic fluency, and semantic fluency tasks
Number of subjects: 20
Study: 16849758

Group type: EXPERIMENTAL
Intervention: Low levels of MGMT expression (97 patients)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Overexpression of MGMT (12 patients)
Number of subjects: 109
Study: 14592280

Group type: EXPERIMENTAL
Intervention: nCPAP plus modafinil (200 mg/day for week 1; 400 mg/day for weeks 2-4)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: nCPAP plus modafinil
Number of subjects: 157

Group type: COMPARATOR
Intervention: nCPAP plus placebo
Number of subjects: 157
Study: 10065667

Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.26 ppm for 2 hours with intermittent exercise)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 14
Study: 7568639

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) reactivity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LF/HF ratio reactivity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HF power reactivity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LF power reactivity
Number of subjects: 22
Study: 2023417

Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg/m2 on the 3rd, 10th, and 17th postoperative days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control arm (observation only)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg/m2
Number of subjects: 135
Study: 7239459

Group type: EXPERIMENTAL
Intervention: Quarterway House program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (center inpatients)
Number of subjects: 0
Study: 31915790

Group type: EXPERIMENTAL
Intervention: Anodal ctDCS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cathodal ctDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 60
Study: 31434413

Group type: EXPERIMENTAL
Intervention: Biofeedback training combined with pelvic floor muscle exercise
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise
Number of subjects: 109

Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 109
Study: 28765118

Group type: EXPERIMENTAL
Intervention: 100 Hz electroacupuncture (EA) to the trigeminal nerve area
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 25828296

Group type: EXPERIMENTAL
Intervention: Chewing gum with 0.6% CPP-ACP for 10 min each day for 1 week before whitening
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chewing gum without CPP-ACP for 10 min each day for 1 week before whitening
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 30
Study: 23230283

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) 0.6 mg/h for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Transdermal glyceryl trinitrate (GTN) 0.6 mg/h (acute administration)
Number of subjects: 12
Study: 21567343

Group type: EXPERIMENTAL
Intervention: Modified auricular composite grafts
Number of subjects: 70
Study: 19029035

Group type: EXPERIMENTAL
Intervention: Stratus OCT
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cirrus OCT
Number of subjects: 104
Study: 17028482

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazepril HCl (5/20 mg/d force‐titrated to 5/40 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Amlodipine besylate monotherapy (5 mg/d force‐titrated to 10 mg/d)
Number of subjects: 70
Study: 15525618

Group type: EXPERIMENTAL
Intervention: 0.2% Ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.2% Levobupivacaine
Number of subjects: 40
Study: 12230021

Group type: EXPERIMENTAL
Intervention: Tokishakuyakusan
Number of subjects: 0
Study: 9717985

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEMZAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 0
Study: 7695323

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil oral suspension with food
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefpodoxime proxetil oral suspension under fasting conditions
Number of subjects: 20
Study: 2695815

Group type: EXPERIMENTAL
Intervention: 100 I.U. of salmon calcitonin (sCT) nasal spray daily (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 I.U. of sCT by subcutaneous injection every second day (n = 10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral calcium supplement, 1 g per day (control group, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcitonin groups (sCT nasal spray and subcutaneous injection)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 40
Study: 334475

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg to 300 mg daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Indomethacin (75 mg to 150 mg daily)
Number of subjects: 23
Study: 6184571

Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 9

Group type: COMPARATOR
Intervention: Verapamil and Labetalol
Number of subjects: 9
Study: 31711858

Group type: EXPERIMENTAL
Intervention: Customized text messages thrice a week
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 248
Study: 29527974

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190
Study: 26965639

Group type: EXPERIMENTAL
Intervention: Menu-plus intervention condition
Number of subjects: 8

Group type: COMPARATOR
Intervention: Menu-only intervention condition
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sales of healthy children's menu items
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ordering behaviors of dining parties
Number of subjects: 8
Study: 24188511

Group type: EXPERIMENTAL
Intervention: Family Focused Therapy (FFT‐CHR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Enhanced Care (EC)
Number of subjects: 66
Study: 22352379

Group type: EXPERIMENTAL
Intervention: Telephonic coaching applying TTM tailoring for exercise and minimal tailoring for stress management
Number of subjects: 3391

Group type: EXPERIMENTAL
Intervention: Internet program applying TTM tailoring for stress management and minimal tailoring for exercise
Number of subjects: 3391

Group type: COMPARATOR
Intervention: Control group receiving assessment only
Number of subjects: 3391
Study: 20556928

Group type: EXPERIMENTAL
Intervention: Once daily fixed combination latanoprost-timolol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Timolol 0.50% twice daily associated with once daily latanoprost
Number of subjects: 44

Group type: COMPARATOR
Intervention: Timolol 0.50% twice daily (control group)
Number of subjects: 44
Study: 16950210

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP) 16 mg/d
Number of subjects: 10

Group type: COMPARATOR
Intervention: BUP placebo
Number of subjects: 10
Study: 15906586

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg once daily
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study: 12074403

Group type: EXPERIMENTAL
Intervention: PSA testing in the general population
Number of subjects: 5371

Group type: EXPERIMENTAL
Intervention: PSA levels 4-10 ng/ml
Number of subjects: 5371

Group type: EXPERIMENTAL
Intervention: PSA levels >10 ng/ml
Number of subjects: 5371

Group type: COMPARATOR
Intervention: Comparison with prostate cancer screening program
Number of subjects: 5371
Study: 10091816

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blocking agents
Number of subjects: 6780

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blocking agents + Enalapril
Number of subjects: 6780

Group type: COMPARATOR
Intervention: Control (nonuse of beta-blockers)
Number of subjects: 6780
Study: 7822398

Group type: EXPERIMENTAL
Intervention: Combined open and percutaneous repair
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 22
Study: 2108614

Group type: COMPARATOR
Intervention: UFT 600 mg/body/day (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UFT 400 mg/body/day for 12 months (Group D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT (dosage between 8 to less than 12 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT (dosage more than 12 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous administration of UFT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinued administration of UFT
Number of subjects: 0
Study: 155295

Group type: EXPERIMENTAL
Intervention: Ipratropium (Atrovent) 0.125 mg x 4 daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Terbutalin (Bricanyl) 5 mg x 4 daily
Number of subjects: 19
Study: 30955055

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder neck descent (BND) during stress by two operators
Number of subjects: 50
Study: 28337029

Group type: EXPERIMENTAL
Intervention: High-protein energy restriction (HP-ER, 1.7 g kg-1 per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal protein energy restriction (NP-ER, 0.9 g kg-1 per day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Energy restriction (ER)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-protein energy restriction (HP-ER)
Number of subjects: 22
Study: 25196890

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23351572

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (GlideScope)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional laryngoscopy (MacIntosh)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (GlideScope) by experienced physicians
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (GlideScope) by inexperienced physicians
Number of subjects: 60